Can-Fite BioPharma Ltd. (TLV: CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA
1.900
0.00 (0.00%)
Jan 21, 2025, 5:24 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
313.92K ILS
Profits / Employee
-3.47M ILS
Market Cap
56.88M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Teva Pharmaceutical Industries | 36,472 |
Danel (Adir Yeoshua) | 3,961 |
Kamada | 378 |
Bait Bakfar | 228 |
Novolog (Pharm-Up 1966) | 955 |
Ilex Medical | 223 |
BrainsWay | 134 |
SofWave Medical | 117 |
Can-Fite BioPharma News
- 22 days ago - Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 2 months ago - Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewsWire
- 2 months ago - Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - GlobeNewsWire
- 3 months ago - Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson - GlobeNewsWire
- 3 months ago - Can-Fite stock rallies 17% on FDA orphan drug designation - Seeking Alpha
- 3 months ago - FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health - GlobeNewsWire